Approximately 15–20% of newly diagnosed invasive breast cancers (IBC) overexpress the human epidermal growth factor receptor 2 (HER2) oncogene, which is associated with increased tumor progression and metastasis [1,2,3]. The gene discussed is ERBB2; the disease is inflammatory breast carcinoma.